Table 1. Clinicopathologic characteristics according to EBV and MMR expression.

Characteristics	Total	EBV			MMR
		Positive	Negative	P value	Deficient	Proficient	P value
Total patients	438	14 (3.3%)	424 (96.8%)		21 (4.8%)	417 (95.2%)
Age, years				0.96			0.04
Median	57	57.5	57		63	56
Range	22-86	43-75	22-86		31-80	22-86
Sex
Male	300 (68.5%)	14 (100%)	286 (67.4%)	0.01	14 (66.7%)	286 (68.6%)	0.85
Female	138 (31.5%)	0	138 (32.6%)		7 (33.3%)	131 (31.4%)
Metastatic site
Liver	73 (19.3%)	3 (4.1%)	70 (95.6%)	0.63	5 (6.8%)	68 (93.2%)	0.37
Lymph node	72 (19.0%)	1 (7.1%)	71 (94.9%)	0.34	2 (2.8%)	70 (97.2%)	0.38
Peritoneum	140 (36.9%)	5 (3.6%)	135 (96.4%)	0.76	3 (2.1%)	137 (97.9%)	0.04
Bone	21 (5.5%)	1 (4.8%)	20 (95.2%)	0.67	0	21 (100%)	0.29
Lung	13 (3.4%)	0	13 (100%)	0.51	0	13 (100%)	0.41
Brain	2 (0.5%)	0	2 (100%)	0.79	0	2 (100%)	0.75
Others	58 (15.3%)	2 (14.3%)	56 (85.7%)	0.91	2 (3.4%)	56 (96.6%)	0.61
Location
Upper/middle	285 (65.1%)	12 (85.7%)	273 (64.4%)	0.04	1 (4.8%)	49 (11.8%)	0.33
Lower	153 (34.9%)	2 (14.3%)	151 (35.6%)		20 (95.2%)	368 (88.2%)
Histology
Differentiated	149 (34.0%)	1 (7.1%)	148 (34.9%)	0.03	12 (57.1%)	137 (32.9%)	0.02
Undifferentiated	289 (66.0%)	13 (92.9%)	276 (65.1%)		9 (42.9%)	280 (67.1%)
Lauren classification (n=245)
Intestinal	98 (40.0%)	3 (33.3%)	95 (40.3%)	0.84	9 (60.0%)	89 (38.7%)	0.25
Diffuse	130 (53.1%)	5 (55.6%)	125 (52.9%)		5 (33.3%)	125 (54.3%)
Mixed	17 (6.9%)	1 (11.1%)	16 (6.8%)		1 (6.7%)	16 (7.0%)
Borrmann (n=406)
1	17 (4.2%)	1 (7.1%)	16 (4.1%)	0.59	1 (5.0%)	16 (4.1%)	0.05
2	71 (17.5%)	4 (28.6%)	67 (17.1%)		5 (25.0%)	66 (17.1%)
3	223 (54.9%)	7 (50.0%)	216 (55.1%)		14 (70.0%)	209 (54.1%)
4	95 (23.4%)	2 (14.3%)	93 (23.7%)		0	95 (24.6%)
Stage
I	23 (5.3%)	0	23 (5.4%)	0.59	1 (4.3%)	22 (5.3%)	0.44
II	87 (19.9%)	3 (21.4%)	84 (19.8%)		7 (33.3%)	80 (19.2%)
III	130 (29.7%)	6 (42.9%)	124 (29.2%)		6 (28.6%)	124 (29.7%)
IV	198 (45.2%)	5 (35.7%)	193 (45.5%)		7 (33.3%)	191 (45.8%)
MSI
MMR-proficient	417 (95.2%)	14 (100%)	403 (95.0%)	0.39	−	−	−
MMR-deficient	21 (4.8%)	0	21 (5.0%)		−	−